Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch & LombBLCO -0.12%77 Earnings Yield (Joel Greenblatt) % is 2.97% as of Jun. 2026, which is 118% above its 10-year median of 1.36. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.42 (Fairly Valued). The stock has 7 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Bausch & Lomb ranks better than 60.82% on this metric.
Bausch & Lomb's Enterprise Value for the quarter that ended in Jun. 2026 was $10,729 Mil.
Bausch & Lomb's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $324 Mil. Bausch & Lomb's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 2.97%.
The historical rank and industry rank for Bausch & Lomb's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
BLCO'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.24 Med: 1.36 Max: 4.13
Current: 3
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Bausch & Lomb was 4.13%. The lowest was 0.24%. And the median was 1.36%.
BLCO's Earnings Yield (Joel Greenblatt) % is ranked better than 60.82% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 0.855
vs BLCO: 3.00
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Bausch & Lomb's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was -0.41%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Bausch & Lomb Earnings Yield (Joel Greenblatt) % Related Terms
Bausch & Lomb Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Bausch & Lombs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Bausch & Lomb's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $324 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 2.97% mean?
Bausch & Lomb (BLCO) has a Earnings Yield (Joel Greenblatt) % of 2.97% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Bausch & Lomb and its competitors. This is 118% above median its historical median of 1.36. Over the past decade, Bausch & Lomb's Earnings Yield (Joel Greenblatt) % has ranged from 0.24 to 4.13. According to the industry distribution chart, Bausch & Lomb ranks #333 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 39.2%.
Is Bausch & Lomb's Earnings Yield (Joel Greenblatt) % too high?
Bausch & Lomb's current Earnings Yield (Joel Greenblatt) % of 2.97% is 118% above median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 4.13. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.86. Bausch & Lomb's value of 2.97% is 247.4% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #333 out of 850 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Earnings Yield (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #333 out of 850 companies for Earnings Yield (Joel Greenblatt) %. This puts Bausch & Lomb in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.86. Bausch & Lomb's value of 2.97% is 247.4% above this benchmark. Historically, Bausch & Lomb's own Earnings Yield (Joel Greenblatt) % has ranged from 0.24 to 4.13 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 0.86, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.86, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current Earnings Yield (Joel Greenblatt) % of 2.97% is 247.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current Earnings Yield (Joel Greenblatt) % is 2.97%, which is 118% above median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $18.42, compared to a current price of $16.96 — trading 7.9% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 2.97%, which is 118% above median its 10-year median of 1.36 and 247.4% above the Medical Devices & Instruments industry median of 0.86. Bausch & Lomb's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Earnings Yield (Joel Greenblatt) % is 2.97% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.96 is trading 7.9% below its estimated GF Value™ of $18.42.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
Earnings Yield (Joel Greenblatt) %: 2.97% (118% above median its 10-year median of 1.36)
GF Value™: $18.42 vs. price of $16.96 (7.9% below fair value)
Industry Position: 247.4% above the Medical Devices & Instruments median (#333 of 850)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
